The 11th invitation to manufacturers of active pharmaceutical ingredients (APIs) to submit an expression of interest (EOI) for API prequalification to the WHO Prequalification Team: medicines (PQTm
Dolutegravir (sodium) manufactured by Styrax Pharma Pvt Ltd has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
The PQT Medicines Annual Quality Assessment Training for regulators will take place from 9 to 12 June 2025.
On 27 March WHO prequalified one additional in vitro diagnostic, the
Nirmatrelvir manufactured by DongBang Future Tech & Life Co., Ltd.
According to WHO’s Procedure for prequalification of pharmaceutical products (TRS 961, Annex 10), “WHO recognizes the evaluation of relevant
The following API was added: